JNPMEDI Signs Strategic Agreement with CHA Global Clinical Trial Center for New Drug Development Research Using Data Solutions

JNPMEDI
27 Apr 2021 · 5 minutes read
JNPMEDI's Maven CDMS solution, which is used to collect and analyze clinical trial data, has signed a strategic agreement for new drug development research used in research on new drug development at CHA global clinical trial center.

JNPMEDI's Maven CDMS solution, which is used to collect and analyze clinical trial data, has signed a strategic agreement for new drug development research used in research on new drug development at CHA global clinical trial center.

Under this agreement, CHA global clinical trial center will more systematically manage and analyze various types of clinical trial data, including researcher clinical trials (IITs) conducted by the institution.

Due to the COVID-19 situation, there is an increasing demand for decentralization to minimize physical visits of subjects and clinical trial monitors (CRA) in the clinical trial process, so the strategy is to prepare for the application of digital transformation technologies necessary soon through cooperation with JNPMEDI.

Tags:
MOU
CHA Bundang Medical Center

Your Partner for a Successful Journey

JNPMEDI has been putting effort on bringing disruption on healthcare industry via integrating digital technologies to clinical research & trial operations.